Insulet Co. (NASDAQ:PODD) Shares Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lifted its holdings in shares of Insulet Co. (NASDAQ:PODD) by 119.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 79,375 shares of the medical instruments supplier’s stock after acquiring an additional 43,147 shares during the period. Assenagon Asset Management S.A. owned 0.11% of Insulet worth $17,223,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in PODD. HighTower Advisors LLC grew its stake in Insulet by 1.4% during the 1st quarter. HighTower Advisors LLC now owns 2,968 shares of the medical instruments supplier’s stock worth $948,000 after buying an additional 41 shares during the last quarter. Moneta Group Investment Advisors LLC grew its stake in Insulet by 7.7% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 743 shares of the medical instruments supplier’s stock worth $214,000 after buying an additional 53 shares during the last quarter. Capula Management Ltd grew its stake in Insulet by 7.4% during the 2nd quarter. Capula Management Ltd now owns 920 shares of the medical instruments supplier’s stock worth $265,000 after buying an additional 63 shares during the last quarter. Fund Management at Engine No. 1 LLC grew its stake in Insulet by 7.7% during the 2nd quarter. Fund Management at Engine No. 1 LLC now owns 907 shares of the medical instruments supplier’s stock worth $262,000 after buying an additional 65 shares during the last quarter. Finally, Cresset Asset Management LLC grew its stake in Insulet by 6.6% during the 1st quarter. Cresset Asset Management LLC now owns 1,102 shares of the medical instruments supplier’s stock worth $293,000 after buying an additional 68 shares during the last quarter.

Insider Transactions at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the completion of the transaction, the director now directly owns 2,567 shares of the company’s stock, valued at $418,215.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Piper Sandler lowered their target price on Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research note on Friday, February 23rd. Barclays lowered their target price on Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research note on Monday, February 26th. Morgan Stanley upgraded Insulet from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $185.00 to $234.00 in a research note on Monday, December 4th. Finally, Robert W. Baird upgraded Insulet from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $180.00 to $238.00 in a research note on Thursday, December 21st. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $250.33.

Insulet Stock Performance

Shares of PODD stock opened at $169.18 on Thursday. The stock has a fifty day moving average price of $183.46 and a 200 day moving average price of $178.40. The stock has a market cap of $11.83 billion, a PE ratio of 58.14, a P/E/G ratio of 2.98 and a beta of 0.98. Insulet Co. has a 1 year low of $125.82 and a 1 year high of $335.91. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.73. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The firm had revenue of $509.80 million during the quarter, compared to analysts’ expectations of $461.26 million. During the same period in the previous year, the firm posted $0.55 earnings per share. Insulet’s revenue was up 37.9% on a year-over-year basis. Sell-side analysts forecast that Insulet Co. will post 3.08 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.